Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 922 across all filing types
Latest filing 2026-05-27 Interim / Quarterly Rep…
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
Śródroczne skrócone skonsolidowane oraz jednostkowe sprawozdanie finansowe sporządzone za okres 3 miesięcy zakończony 31 marca 2026 roku
Interim / Quarterly Report Classification · 98% confidence The document is titled "Środroczne skrócone skonsolidowane oraz jednostkowe sprawozdanie finansowe" for the three-month period ending March 31, 2026. It contains full interim consolidated and standalone financial statements (statement of profit and loss, balance sheet, cash flow, equity changes) and extensive notes. This matches the definition of an Interim/Quarterly Report rather than an announcement or summary. Hence it is classified as IR. Q1 2026
2026-05-27 Polish
Rozszerzony Skonsolidowany Raport kwartalny Grupy Kapitałowej Captor Therapeutics za 01.01.2026 - 31.03.2026
Interim / Quarterly Report Classification · 98% confidence The document is titled “Rozszerzony Skonsolidowany Raport kwartalny Grupy Kapitałowej Captor Therapeutics za okres 01.01.2026 r. – 31.03.2026 r.” (“Extended Consolidated Quarterly Report for the period 1 January 2026 to 31 March 2026”). It contains detailed interim financial statements (condensed consolidated and standalone statements of profit and loss, balance sheet, cash flows), management commentary, analysis of financial position, and key events. This meets the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-27 Polish
informację o ogólnej liczbie głosów
Proxy Solicitation & Information Statement Classification · 72% confidence The document provides detailed information on the total number of shares and voting rights by share class in advance of an Extraordinary General Meeting. It is part of the informational materials sent to shareholders to prepare for and solicit votes at the meeting, rather than reporting results or issuing new shares. This matches the Proxy Solicitation & Information Statement definition.
2026-05-22 Polish
wzór instrukcji wykonywania prawa głosu przez pełnomocnika
Proxy Solicitation & Information Statement Classification · 85% confidence The document is an instruction for voting by proxy at the Ordinary General Meeting (AGM) of Captor Therapeutics S.A. on June 19, 2026. It lists agenda items and proposed resolutions with voting checkboxes for a proxy holder. This is not the annual report itself, nor the results post-meeting, but materials sent to shareholders to solicit and guide their votes. Therefore it is classified as a Proxy Solicitation & Information Statement (PSI).
2026-05-22 Polish
wzór pełnomocnictwa
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a proxy authorization form (Formularz Pełnomocnictwa) allowing shareholders to appoint a proxy to vote at the company’s Ordinary General Meeting on June 19, 2026. This is part of materials sent to shareholders to solicit votes and proxies for the AGM, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-22 Polish
sprawozdanie Rady Nadzorczej Spółki za rok 2025
Governance Information Classification · 90% confidence The document is a formal Polish Supervisory Board Report (“Sprawozdanie Rady Nadzorczej”) detailing the legal basis, composition, committees, independence assessments, internal controls, and governance practices of the Supervisory Board for the 2025 financial year. It is not an Annual Report (10-K/annual report), nor an announcement of a meeting or proxy materials; rather it focuses on the company’s governance structure and practices. This best fits the Governance Information category (CGR).
2026-05-22 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.